RTI Surgical has appointed Chad Croasdale as its new chief commercial officer.
Croasdale boasts over two decades of commercial and financial leadership in the medical technology industry. Before joining RTI, he was president and chief commercial officer of 270Surgical, maker of the first FDA-cleared 270-degree field-of-view laparoscopic camera on the market.
Prior to that, Croasdale spent over 18 years at Stryker in roles of increasing responsibility, culminating as VP and GM of Stryker Communications, Endoscopy. Chad began his healthcare career as a physical therapist that specialized in sports medicine.
“I am excited to join RTI Surgical, a company with a strong reputation for its commitment to quality, innovation and patients, and a clear strategy for growth,” Croasdale told the press. “I look forward to working with the team and our OEM partners to develop biomaterials and expand our reach to even more patients.”
“We are delighted to welcome Chad to RTI,” added RTI Surgical president and CEO Olivier Visa. “His extensive experience in driving commercial success will be invaluable as we continue to establish ourselves as the CDMO partner of choice in regenerative medicine, leveraging our unique portfolio of xenograft and allograft biomaterials to improve patient outcomes.”
More about RTI Surgical
The Alachua, Fla.-based company is a regenerative medicine contract development and manufacturing organization (CDMO). The company partners with OEMs to identify clinical problems and develop customized solutions to promote healing, accelerate recovery, and prevent complications.
The company touts a portfolio of biomaterials for specialized clinical segments including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery.